Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Cerilliant
Daiichi Sankyo
Julphar
Merck
Medtronic
McKinsey
AstraZeneca
Teva

Generated: September 19, 2018

DrugPatentWatch Database Preview

NEUPRO Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Neupro, and what generic alternatives are available?

Neupro is a drug marketed by Ucb Inc and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in NEUPRO is rotigotine. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rotigotine profile page.

Drug patent expirations by year for NEUPRO
Generic Entry Opportunity Date for NEUPRO
Generic Entry Date for NEUPRO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FILM, EXTENDED RELEASE;TRANSDERMAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for NEUPRO
(-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol
(-)-N-0437
(2S)-2-[propyl-[2-(2-thienyl)ethyl]amino]tetralin-5-ol
(6S)-6-(propyl-(2-thiophen-2-ylethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol
(6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol
(6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
(S)-(-)-Rotigotine
(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol
(S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol
(S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol
(S)-6-[Propyl-(2-thiophen-2-yl-ethyl)-amino]-5,6,7,8-tetrahydro-naphthalen-1-ol
1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl (2-(2-thienyl)ethyl)amino-(6S)-
1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (6S)-
2-(N-n-Propyl-N-2-thienylethylamino)-5-hydroxytetralin
2696AH
572R932
87T4T8BO2E
99755-59-6
A846076
AB0088886
AC-3547
AC1L1QQG
AJ-08188
AKOS016340728
AN-12885
API0026245
BC677693
BDBM50123626
C19H25NOS
CAS-99755-59-6
CHEBI:135351
CHEMBL1303
CS-0376
CTK8E7903
Cyclopentylcytosine
D05768
D08XAW
D09OQV
DB05271
DSSTox_CID_26772
DSSTox_GSID_46772
DSSTox_RID_81893
DTXSID5046772
EX-A1164
FT-0771906
GTPL941
HSDB 8254
HY-75502
J-502471
KFQYTPMOWPVWEJ-INIZCTEOSA-N
KS-00002WXX
Leganto
LS-178435
MFCD00870193
MolPort-005-941-578
N 0437
N 0437, (-)-isomer
N 0923
N-0437
N-0923
NCGC00168748-01
NCGC00168748-02
Neupro (TN)
PubChem16423
RL06136
Rotigotine
Rotigotine (JAN/USAN/INN)
Rotigotine (USAN/INN)
Rotigotine [USAN:INN:BAN]
Rotigotine [USAN:INN]
Rotigotine CDS
Rotigotine CDS Patch
RT-015446
s4274
SC-22242
SCHEMBL1088585
SPM 962
SPM-936
SPM-937
SPM-962
SS-4572
Tox21_112627
Tox21_112627_1
UNII-5QTR54Z0E1 component KFQYTPMOWPVWEJ-INIZCTEOSA-N
UNII-87T4T8BO2E
W-5179
ZINC4028

US Patents and Regulatory Information for NEUPRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-003 May 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for NEUPRO
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Transdermal Film 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr ➤ Subscribe ➤ Sign Up

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for NEUPRO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
269 Luxembourg ➤ Sign Up 91269, EXPIRES: 20210215
1033978/01 Switzerland ➤ Sign Up TEILUEBERTRAGUNG
00236 Netherlands ➤ Sign Up PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001-013 20060215
2006 00020 Denmark ➤ Sign Up PRODUCT NAME: ROTIGOTINE
C0025 France ➤ Sign Up PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 20060215
24/2006 Austria ➤ Sign Up PRODUCT NAME: ROTIGOTINE
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Cerilliant
Daiichi Sankyo
Julphar
Merck
Medtronic
McKinsey
AstraZeneca
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.